[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601357":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Jules Bordet Institute","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"patient with liver metastasis from colorectal cancer",null,[12],"Diagnostic Test: FAPI PET\u002FCT",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","FAPI PET\u002FCT","Patient will undergo FAPI PET\u002FCT Prior to surgery",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Loubna Taraji, MS","CONTACT","02.541.37.81","loubna.taraji@hubruxelles.be",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Institut Jules Bordet","RECRUITING","Brussels","1070","Belgium","BE",{"type":34,"coordinates":35},"Point",[36,37],4.34878,50.85045,{"lat":37,"lon":36},[40,44,47],{"name":41,"role":22,"phone":42,"phoneExt":10,"email":43},"Irina Ortansa Vierasu, MD","02.555.82.80","o-i.vierasu@hubruxelles.be",{"name":45,"role":22,"phone":46,"phoneExt":10,"email":10},"Loubna TARAJI, MS","02.541.3781",{"name":41,"role":48,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100601357","the-role-of-the-imaging-fapi-petct-in-exploring-the-microenvironment-of-colorectal-cancer-liver-metastases-100601357",false,"NCT07109440","The Role of the Imaging FAPI PET\u002FCT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases","The Role of FAPI PET\u002FCT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases: Non-randomized Phase II Molecular Imaging Study","FOAM","Inclusion Criteria:\n\n* Age above 18 years.\n* Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET\u002FCT)\n* Naïve for treatment or after neoadjuvant chemotherapy\n* Scheduled for liver metastasis resection\n* ECOG Performance status ≤2.\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Non-resectable liver metastases\n* Pregnant and lactating women\n* Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.","ALL","18 Years",{"count":62,"type":63},50,"ESTIMATED","INTERVENTIONAL",[66],"NA","FAPI PET\u002FCT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET\u002FCT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery",[69],"Liver Metastases From Colorectal Cancer",[71,16,72,73],"liver metastases from colorectal cancer","HGP","CAF","2025-08-06",{"date":76,"type":77},"2025-08-07","ACTUAL",{"date":79,"type":77},"2025-05-09",{"date":81,"type":63},"2028-12",{"name":5,"class":6},1]